Independent Medical Education Grant for Transthyretin Amyloidosis
Independent Medical Education Grant for Transthyretin Amyloidosis supports educators providing clinician education on hereditary disease recognition, diagnosis, and treatment to improve patient care.
Funder: AstraZeneca United States
Due Dates: Rolling (grant review and approval) | January 15–July 31, 2027 (anticipated program start window)
Funding Amounts: Independent medical education grant support
Summary: Supports independent medical education on hereditary transthyretin amyloidosis to improve disease recognition, diagnosis, treatment knowledge, and patient care.
Key Information: Applications are welcomed from educational providers delivering independent medical education (IME/CME).
Description
AstraZeneca’s Medical Education Grants Office supports independent medical education on hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) and hereditary transthyretin amyloid mixed phenotype (ATTRv-CM with ATTRv-PN). The program focuses on expanding disease awareness, recognizing disease characteristics that can prompt early diagnosis, sharing current and emerging clinical treatment data, and developing care plans that benefit patients with ATTRv.
The grant supports education addressing documented unmet educational needs to help healthcare professionals improve patient care and outcomes. Recommended learning formats combine live or virtual live education, including audio or video, with an enduring component and certified education credit for the target audience. Optional formats include podcasts, panel discussions, simulations, patient case studies, and print materials.
